Evidence map›Paper›PMID 32861387›Full record

Observational studyIndian heart journal

Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging.

Arsalan Rafiq, Tausif Chughtai, Umair Ashraf, Yash Patel, Farbod Raiszadeh, Eduard Sklyar, Maryam Afshar, Jonathan N Bella, Gayathri Kamalakkannan

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Arsalan RafiqBronxCare Health System, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: arafiq@geisinger.edu.
Tausif ChughtaiBronxCare Health System, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: tchughta@bronxleb.org.
Umair AshrafBronxCare Health System, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: 84.umair@gmail.com.
Yash PatelMount Sinai St. Luke's - Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: dryashpatel21@gmail.com.
Farbod RaiszadehBronxCare Health System, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: fraiszad@gmail.com.
Eduard SklyarBronxCare Health System, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: esklyar@bronxleb.org.
Maryam AfsharBronxCare Health System, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: maryam.afshar2@VA.gov.
Jonathan N BellaBronxCare Health System, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: jbella@bronxleb.org.
Gayathri KamalakkannanBronxCare Health System, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: gkamalak@bronxleb.org.
Mount Sinai Health System · USIcahn School of Medicine at Mount Sinai · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regression analyses, there was no statistical significance of QTc prolongation when adjusted for ischemia/fixed perfusion defect on MPI and QT prolonging medications being taken prior to stress testing. However, a positive stress ECG after Regadenoson injection had a statistical significance (p value 0.0004). Regadenoson is a safe drug for use in MPI with little, if any, side effects of major clinical significance.

Indexed as

Adenosine A2 Receptor AgonistsElectrocardiographyFemaleHumansLong QT SyndromeMaleMiddle AgedMyocardial Perfusion ImagingPurinesPyrazolesRetrospective StudiesAdenosine A2 Receptor AgonistsPurinesPyrazolesregadenosonMyocardial perfusion imagingQTc interval prolongationRegadenoson

Identifiers

PMID32861387
PMCPMC7474107
OpenAlexW3039844948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.